Rigel Pharmaceuticals issues Dear Healthcare Provider letter for Gavreto

Rigel Pharmaceuticals (RIGL) is issuing a Dear Health Care Provider – DHCP – letter related to a new safety signal for Gavreto – pralsetinib – after consultation with the FDA. Gavreto is for the treatment of adult patients with metastatic rearranged during transfection fusion-positive non-small cell lung cancer as detected by a FDA approved test and adult and pediatric patients 12 years of age and older with advanced or metastatic RET fusion-positive thyroid cancer who require systemic therapy and who are radioactive iodine-refractory. Healthcare providers and patients are encouraged to report adverse events in patients taking Gavreto to the Rigel Medical Communications Center. Rigel announced the completion of the transfer to Rigel of the New Drug Application for Gavreto from Blueprint Medicines Corporation in June.